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Introduction. Sentinel lymph node biopsy (SLNB) in patients with pure ductal carcinoma in situ (DCIS) has been a matter of
debate due to very low rate of axillary metastases. We therefore aimed to identify factors in a single institutional series to select
patients who may beneﬁt from SLNB. Material and Methods. Patients, diagnosed with pure DCIS (n = 63) between July 2000 and
March 2011, were reviewed. All the sentinel lymph nodes were examined by serial sectioning (50µm) of the entire lymph node and
H&E staining, and by cytokeratin immunostaining in suspicious cases. Results. Median age was 51 (range, 30–79). Of 63 patients,
40 cases (63.5%) with pure DCIS underwent SLN, and 2 of them had a positive SLN (5%). In both 2 cases with SLN metastases,
only one sentinel lymph node was involved with tumor cells. Patients who underwent SLNB were more likely to have a tumor size
>30mm or DCIS with intermediate and high nuclear grade or a mastectomy in univariate and multivariate analyses. Conclusion.
In our series, we found a slightly higher rate of SLNB positivity in patients with pure DCIS than the large series reported elsewhere.
ThismayeitherbeduetothemeticulousexaminationofSLNsbyserialsectioningtechniqueorduetoourpatientselectioncriteria
or both.
1.Introduction
Ductal carcinoma in situ (DCIS) of the breast is a preinvasive
lesion with theoretically no potential for lymph node or
distant metastases by deﬁnition. So far the management of
axilla in DCIS has dramatically changed. Axillary dissection
rates have been decreased since 1990s [1] because it has been
shown that omission of axillary dissection in patients with
pure in situ disease had no adverse eﬀect on survival or
recurrence [1, 2].
In the era of sentinel lymph node biopsy (SLNB) which
has been well established in early invasive breast cancer with
low axillary recurrence, the center of argument in DCIS has
become “to do or not to do SLNB in patients with DCIS?”
Today, some authors still believe that there is a subset of
patientsathighriskformicroinvasivediseaseandsubsequent
axillary metastasis who may beneﬁt from the SLN biopsy
(SLNB) [5, 10–13]. However, there have been reports which
discourage SLNB in patients with pure DCIS due to very low
rate of axillary metastasis [3, 4, 14–17].
The ﬂaw is that deﬁnitive diagnosis of DCIS cannot
be made unless the ﬁnal histopathological examination is
done. However, the surgeon mostly has to decide on whether
SLNB is to be performed based on a preoperative stereotactic
core-needle biopsy or vacuum aspiration biopsy or tumor
characteristics or surgery type. Many surgeons advocate
SLNB for patients with DCIS in whom mastectomy was
planned to avoid an unnecessary axillary clearance in case
an invasive focus has been identiﬁed in the ﬁnal pathology.
Presence of high grade DCIS or presence of comedonecrosis,
and diagnosis of invasive component by core-needle biopsy,
andmammographicDCISsizeofatleast4cmwereidentiﬁed
as independent risk factors for invasion [12, 18]. However,
no risk factors could be found that were predictive for
sentinel lymph node metastasis [18]. Furthermore, presence
of comedonecrosis and larger mammographic DCIS size
were independent predictors of patients’ undergoing SLNB
with a presurgical diagnosis of DCIS in core biopsy [12].
In the present study, we reviewed the patients with a
deﬁnitive diagnosis of pure DCIS in a single institution2 ISRN Surgery
series to identify factors to select patients who may beneﬁt
from SLNB, and to deﬁne our surgical management in these
patients.
2.MaterialsandMethods
Of 699 patients operated for breast cancer at our institution
between July 2000 and March 2011, 68 patients (9.7%) were
diagnosed with pure DCIS or DCIS associated with microin-
vasion. Patients with DCIS associated with microinvasion
(n = 5) were excluded from the study, and 63 patients with
pure DCIS were reviewed. The data regarding patient and
tumor characteristics were collected form medical records:
age at diagnosis, menopausal status, tumor size, nuclear
grade, presence of comedo necrosis, type of biopsy (core
biopsy, vacuum aspirated biopsy, excisional biopsy by wire-
needle localisation or radioguided occult lesion localisation
(ROLL)), type of breast surgery (mastectomy versus breast
conservation), margin status, estrogen receptor (ER) stain-
ing,progesteronereceptor(PR)staining,HER2/neustaining,
presence of SLNB, and pathological examination of sentinel
lymph nodes. The excisional biopsy technique to remove
the nonpalpable lesion by ROLL has been described before
in detail [19]. The decision on whether a SLNB was to be
performed was made for each individual patient separately.
Lymphatic mapping was done with a combined tech-
nique of lymphoscintigraphy after radiocolloid injection at
the day of surgery and subareolar methylene blue injection
followedbybreastmassage.Allthelymphnodescoloredwith
blue dye and showed radioactivity with gamma probe were
removed and were sent for intraoperative evaluation by the
pathologist. Brieﬂy, the sentinel lymph node(s) was bisected
fresh along its long axis through the hilus or the entering
point of aﬀerent lymphatic if it was colored with blue. The
node was sliced in 2mm thickness. Scrape preparations
especially from the hilus and from 2 to 4 faces pairs were
made and were stained with hematoxylin and eosin (H&E).
In the presence of suspicious cells, frozen section from the
related slice of the lymph node was made. Finally, the lymph
nodes were embedded in paraﬃn. The entire sentinel lymph
nodes were serially sectioned with 50µm intervals, and two
sequential slices with 3µm thickness were prepared. One
of these sequential sections was stained with H&E, and the
other one was spared for immunohistochemistry in cases
with suspicious atypical cells by H&E to be stained by using
a pan-cytokeratin antibody (Novocastra, RTU-PAN-CK,
Newcastle, UK). SLN metastases were classiﬁed according
to the 7th edition of the American Joint Committee on
Cancer(AJCC)stagingsystem[20]asfollows:isolatedtumor
cells (ITC) were deﬁned as isolated tumor cells or clusters
≤0.2mm in maximum diameter; micrometastasis were
deﬁned as metastases >0.2mm but <2mm; macrometastasis
as >2mm.
If the breast lesion consisted of microcalciﬁcations with
or without a mass, the entire specimen was sampled after
inking and embedded in paraﬃn after orientation. In cases
with a palpable mass, complete sampling of the mass and
surgical margins were performed and samples from the
surrounding tissue were evaluated for margin evaluation
after the specimen was inked. In cases of mastectomy,
in addition to complete sampling of microcalciﬁcations
or mass, samples of the surrounding tissue and nipple
areola complex were also examined. The distance of the
tumor to the specimen’s inked edge was reported for every
marking margin and the margin width was considered as
the narrowest distance between the tumor and any inked
margin. Microinvasion was deﬁned according to the 7th
edition of AJCC staging system [20], which was considered
as a microscopic focus of invasion of cancer cells extending
beyond the basement membrane into the adjacent tissue,
with no focus greater than 0.1cm in dimension.
The histopathologic diagnosis and classiﬁcation of DCIS
were done according to criteria as deﬁned by Rosen and
Oberman [21]. Grading of DCIS was categorized as “well-,
intermediately, and poorly” diﬀerentiated DCIS according
to the classiﬁcation of Holland et al. [22]. Estrogen and
progesterone receptor status was evaluated along with
HER2/neu protein overexpression as well. Immunostains for
ER and PR were performed by using ER (Novocastra (6F11),
Newcastle, UK) and PR (Novocastra (PGR-312), Newcastle,
UK) antibodies on full sections, and cases with 10% or more
positivestainingwereconsideredaspositive.HER2positivity
was determined based on immunohistochemistry staining
by using HER2/neu antibody (Ventana (HER2/neu 4B5),
Tucson, Arizona, USA).
The statistical analyses were performed by using the
Statistical Package for the Social Sciences (SPSS) program,
version 15.0 (SPSS Inc., Chicago, IL, USA). Predictive factors
of patients undergoing SLNB were investigated by univariate
analyses using Fisher’s exact test. The statistically signiﬁcant
variableswerefurtheranalyzedbylogisticregressionanalyses
to identify the independent factors. A P value equal or less
than 0.05 was considered signiﬁcant.
3. Results
Sixty-three patients with pure DCIS were reviewed in this
study. Median age was 51 (range, 30–79). Thirty-six patients
(57.1%) presented with pleomorphic microcalciﬁcations in
mammogram without clinical symptom whereas 6 patients
(9.5%) presented with pathological nipple discharge and 18
(28.6%) had a palpable mass in physical exam. Two patients
(3.2%) had a mass in ultrasound or MRI, whereas one
patient had an asymmetric density in the aﬀected breast
mammogram. Preoperative diagnosis was made by core
biopsy in 12 patients (19%), and by vacuum aspirated biopsy
in 4 patients (6.3%), respectively. However, the majority
of patients (n = 47, 74.6%) underwent excisional biopsy
by wire-needle localisation (n = 42), or ROLL (n = 5)
for pathologic diagnosis. Intraoperative frozen section was
utilized in 35 cases (55.6%).
Mastectomy was performed in 32 patients (50.8%) due
to multifocal or multicentric disease, whereas 31 patients
(49.2%) underwent breast conserving surgery. Forty patients
(63.5%) with pure DCIS underwent SLNB, and a median
number of 2 SLNs (range, 1–8) were harvested duringISRN Surgery 3
Table 1: Univariate analyses for predicting factors associated with
the presence of sentinel lymph node biopsy (SLNB) in patients with
pure ductal carcinoma in situ (DCIS).
Factors
Use of SLNB
(+) (%)
(n = 40)
P value
Age: 0.611
<50 (n = 30) versus ≥50 (n = 33)
18 (60%)
versus 22
(66.7%)
Palpable mass∗: 0.017
(−)v e r s u s( + )
23 (44.2%)
versus 16
(88.9%)
Tumor size: 0.006
≤30mm (n = 40) versus >30mm
(n = 23)
20 (50%)
versus 20
(87%)
Comedo necrosis∗: 0.026
present (n = 31) versus absent
(n = 26)
24 (77.4%)
versus 12
(46%)
Nuclear grade∗: 0.012
low (n = 15) versus intermediate and
high (n = 34)
5 (33.3%)
versus 25
(73.5%)
Type of surgery: 0.001
breast conservation (n = 31) versus
mastectomy (n = 32)
13 (41.9%)
versus 27
(84.4%)
Multifocality/multicentricity: 0.182
(−)( n = 28) versus (+) (n = 34)
21 (75%)
versus 19
(55.9%)
Estrogen receptor status∗: 0.622
(+) (n = 21) versus (−)( n = 7)
17 (81%)
versus 5
(71.4%)
Progesteron receptor status∗: 0.634
(+) (n = 18) versus (−)( n = 10)
15 (83.3%)
versus 7
(70%)
HER2/neu∗: 0.364
( I H C3 + )o rF I S H( + )( n = 16) versus
other (n = 9)
11 (68.8%)
versus 8
(88.9%)
∗Unknown data were excluded from the analysis.
the procedure. Two patients were found to have a positive
SLNB (5%). Of patients with SLN positivity, one patient
(2.5%)wasdemonstratedtohaveisolatedtumorcells(ITCs),
whereas one patient had macrometastasis (2.5%). Axillary
lymph node dissection was performed in one patient with
macrometastasis. In all 2 cases with SLN metastases, only
one sentinel lymph node was involved with tumor cells,
whereas all the other sentinel and nonsentinel lymph nodes
Table 2: Multivariate analyses for predictive factors associated with
the presence of SLNB in patients with pure DCIS.
Factors Odds ratio
(95% CI) P value
Nuclear grade intermediate and high
(versus low) 8.1 (1.4–48.2) 0.021
Tumor size >30mm (versus ≤30mm) 5.5 (0.9–31.6) 0.059
Mastectomy (versus breast
conservation) 14 (2.3–84.3) 0.004
Palpable mass (versus nonpalpable) 3.5 (0.6–21.6) 0.186
were found to be reactive. The patient with macrometastatis
received chemotherapy and adjuvant hormonotherapy for
5 years. The other patient with ITC underwent breast
irradiation and received tamoxifen for 5 years. Both of the
patients with SLN positivity had high grade tumors, either a
palpable mass or a lesion more than 3cm.
Patients,who underwent SLNB, were more likely to have
a palpable mass, or a tumor size >30mm or DCIS with
intermediate or high nuclear grade or comedonecrosis or
mastectomy due to extensive disease (Table 1). Tumor size,
nuclear grade, mastectomy, presence of palpable mass were
analyzed in logistic regression model. Performing mastec-
tomy, tumor size >30 mm, and presence of intermediate or
high nuclear grade were signiﬁcant independent predictive
factors to do a sentinel lymph node biopsy in logistic
regression analysis (Table 2). Other factors including age
>50, estrogen or progesteron receptor status, or HER-
2/neu positivity did not signiﬁcantly inﬂuence the surgeon’s
decision to perform SLNB.
4. Discussion
Although ductal carcinoma in situ (DCIS) is a lesion which
hasatheoreticalriskof0%formetastases,axillarymetastases
have been found in 1-2% of the patients treated with axillary
dissection [23]. Furthermore, SLN positivity in DCIS is
higher than reported axillary positivity ranging between
1% and 13% in published reports as shown in Table 3 [3–
5, 9, 24–27]. In a metaanalysis of 3166 patients, the incidence
of SLN metastases was 7.4% in patients with a preoperative
diagnosis of DCIS compared with 3.7% in patients with
a deﬁnitive postoperative diagnosis of DCIS alone [13].
Klauber-De More et al. [9] reported 12% SLN positivity
in DCIS but when patients with microinvasive focus and
patients with stromal and vascular invasion were excluded,
the incidence decreased to 6.5%. Pendas et al. [26]r e p o r t e d
4.6% positivity with 4 positive SLNs (by H&E and IHC) in
86 patients with pure DCIS. In a series of 854 patients with
pure DCIS, the overall risk of SLN metastases was found to
be 1.9% by Intra et al. [3]. This ratio dropped to 1.4% when
presence of ITC in SLNs was considered negative according
to the last TNM classiﬁcation [3, 28]. In concordance with
some studies [26], we found the SLN positivity as 5% in
pure DCIS which is a slightly higher rate of SLN positivity
in published large series [3, 13].4 ISRN Surgery
Table 3: Sentinel lymph node positivity in patients diagnosed with pure ductal carcinoma in situ (DCIS) determined by hematoxylin and
eosin (H&E) staining or immunohistochemistry (IHC).
Institution No. of
patients (n)
Sentinel lymph node positivity in pure
DCIS: by H&E or (IHC)
European Institute of Oncology, Milan [3] 854 1.9%
University of Padova, Italy [4] 102 1%
Lee Moﬃtt Cancer Center, FL, USA [5] 195 13%: 6.5% by H&E; 6.5% by IHC
Lee Moﬃtt Cancer Center, FL, USA [6] 559 5%: 1.5% by H&E, 3.5% by IHC
University of Paris, France [7] 110 6%
Sibley Memorial Hospital, Washington DC, USA [8] 110 7.2%: 3.6% by H&E; 3.6% by IHC
Memorial Sloan Kettering Cancer Center [9] 76 12%
Acibadem University, Faculty of Medicine, Istanbul (present
study) 40 5%: 2.5% by H&E, 2.5% by IHC
The variation in SLN positivity may be attributed to
evolution of sentinel node biopsy techniques, diﬀerent
preoperative diagnostic methods, variations in pathologi-
cal examination including extent of tissue sampling and
evaluation of the SLNs with H&E or IHC or both, and
small patient numbers in some series [13, 29]. Some reports
doubled their node positivity frequencies by using IHC to
detect SLN involvement [5, 8, 30]. In a study by Lata et
al. [31], in 13% of the patients, SLNs were shown to be
involved by tumor cells by IHC methods but no signiﬁcant
association with local, regional or distant recurrence was
shown. Wilkie et al. [6] reported metastatic lymph nodes
in 5% of 559 patients with a ﬁnal diagnosis of DCIS after
surgical resection and 70% of them were detected only by
IHC. In our series, SLNs were meticulously examined with
H&E staining after serially sectioned with 50µm intervals,
but IHC was only performed in the presence of suspicious
cells.
Most of the SLN metastases of DCIS consist of micro-
metastases and ITC, and the SLN is the only aﬀected node
usually even in the presence of macrometastasis [9, 25, 31].
Similarly, in our series, only one SLN was involved in
both cases whereas all the other sentinel and nonsentinel
nodes were reactive. This has been mostly attributed to an
unrecognized invasive focus in the breast or metastases sub-
sequent to an invasive local recurrence or due to the diﬀerent
examination methods such as H&E or immunohistochem-
istry [23, 31].
The presence of ITC or micrometastases in the SLN in
patientswithDCISisanintriguingissuewithunclearclinical
implications. Broekhuizen et al. [30] reported an increase in
incidence of lymph node metastases after revision with IHC
from 1.4% to 10.6% in pure DCIS patients. They mentioned
that the cells might have represented a false positive ﬁnding
associated with microembolism of breast epithelial/tumor
tissue that had been dislodged to the lymphatic system by
a sampling procedure, but they could not ﬁnd any evidence
of mechanical displacement. However, Bleiweiss et al. [32]
demonstrated that CK positive cells in the positive SLNs
had diﬀerent histologic and immunohistochemical charac-
teristics from the primary intraductal carcinoma involving
an intraductal papilloma. They suggested that SLNB should
not have been a routine procedure until the patient has a
histologically proven invasive tumor.
Because of low incidence of the SLN involvement, the
routine use of SLNB in pure DCIS is discouraged [3, 14,
16]. However, diagnosis of pure DCIS can only be made
after ﬁnal pathological examination, and in case of an
invasive focus in paraﬃn sections, reoperation for SLNB is
needed. It has been reported that an underestimation of
an invasive focus is present in 10–42% of patients when
preoperative diagnosis is made by core needle biopsy or
vacuum aspiration biopsy as in clinical practice [7, 33–
38]. When literature that attempted to deﬁne a subgroup
of patients in whom a second operation for SLNB could
be avoided, most of the authors have reported that a
palpable mass, mammographic mass, a high grade lesion,
and a large size were associated with a signiﬁcant risk of
invasive disease in the ﬁnal resection specimen despite some
inconsistencies between the studies [12, 13, 39–41]. Yen et al.
[12] mentioned about 4 independent predictors of invasive
cancer on ﬁnal pathology which were age <55, diagnosis by
core needle biopsy, mammographic DCIS size >4cm, and
high grade DCIS. Furthermore, presence of comedonecro-
sis and larger mammographic DCIS size were found as
independent predictors of patients’ undergoing SLNB in
multivariate analysis. Sakr et al. [7] suggested that DCIS
with microinvasion or diﬀuse DCIS requiring mastectomy
(including DCIS more than 30mm) was the main risk factor
for SLN metastasis in a 110-patient series. However, Intra
et al. [3] reported that the risk of SLN metastases did not
seem to be correlated with the comedocarcinoma subtype,
presence of necrosis, tumor grade, hormone receptor status,
Ki67, HER2/neu status, multifocality, or type of surgery.
The most common architectural patterns were solid and
cribriform patterns, but not comedo among those patients
with pure DCIS and positive SLNs. The authors found
age younger than 50 and mass as clinical presentation to
be important factors predicting the likelihood of the SLN
metastasis. On the other hand, there have also been some
other reports that did not identify any signiﬁcant predictive
risk factors [5, 18, 42, 43].
Our surgical approach to perform SLNB in the same
session with deﬁnitive operation is in concordance with theISRN Surgery 5
published literature [3, 5, 12, 44]. SLNB was not used as
a standard procedure in treatment of all DCIS patients.
Factors signiﬁcantly aﬀecting our approach were performing
mastectomy, the size of the tumor (>30mm), and presence
of intermediate and high nuclear grade. Patients with large
comedo DCIS, large solid tumors, diﬀuse or multicentric
microcalciﬁcations, recurrent lesions, and high grade DCIS
were also scheduled for SLNB. In all cases, meticulous
examination of the tumor specimen was done to exclude
microinvasive foci and to decrease the prevalence of unex-
pected SLN metastases [10].
5. Conclusion
In our series, we found a relatively higher SLNB positivity
in patients with pure DCIS than the large series reported
elsewhere. This may either be due to the meticulous exam-
ination of SLNs by serial sectioning technique or due to our
patient selection criteria or both. Although the importance
of presence of ITC in SLNs has not been clariﬁed yet, it may
be reasonable to perform SLN in selected patients with pure
DCIS. SLNB should be considered in cases of DCIS where
there is a strong doubt of invasion at the deﬁnitive pathology
as in patients with large tumors or diﬀuse pluricentric
microcalciﬁcations undergoing mastectomy or high grade
DCIS with comedonecrosis or solid cribriform pattern.
References
[ 1 ]N .N .B a x t e r ,B .A .V i r n i g ,S .B .D u r h a m ,a n dT .M .T u t t l e ,
“Trends in the treatment of ductal carcinoma in situ of the
breast,” Journal of the National Cancer Institute, vol. 96, no. 6,
pp. 443–448, 2004.
[2] H. Mabry, A. E. Giuliano, and M. J. Silverstein, “What is the
value of axillary dissection or sentinel node biopsy in patients
with ductal carcinoma in situ?” American Journal of Surgery,
vol. 192, no. 4, pp. 455–457, 2006.
[3] M.Intra,N.Rotmensz,P.Veronesietal.,“Sentinelnodebiopsy
is not a standard procedure in ductal carcinoma in situ of the
breast: the experience of the european institute of oncology on
854 patients in 10 years,” Annals of Surgery, vol. 247, no. 2, pp.
315–319, 2008.
[4] G. Zavagno, P.Carcoforo, R.Marconato etal., “Roleofaxillary
sentinel lymph node biopsy in patients with pure ductal
carcinoma in situ of the breast,” BMC Cancer, vol. 5, article
no. 28, pp. 28–33, 2005.
[ 5 ]C .E .C o x ,K .N g u y e n ,R .J .G r a ye ta l . ,“ I m p o r t a n c eo f
lymphatic mapping in ductal carcinoma in situ (DCIS): why
map DCIS?” American Surgeon, vol. 67, no. 6, pp. 513–519,
2001.
[6] C. Wilkie, L. White, E. Dupont, A. Cantor, and C. E. Cox,
“An update of sentinel lymph node mapping in patients with
ductal carcinoma in situ,” American Journal of Surgery, vol.
190, no. 4, pp. 563–566, 2005.
[7] R. Sakr, C. Bezu, I. Raoust et al., “The sentinel lymph
node procedure for patients with preoperative diagnosis of
ductal carcinoma in situ: risk factors for unsuspected invasive
diseaseandformetastaticsentinellymphnodes,”International
Journal of Clinical Practice, vol. 62, no. 11, pp. 1730–1735,
2008.
[8] A.Katz,I.Gage,S.Evansetal.,“Sentinellymphnodepositivity
of patients with ductal carcinoma in situ or microinvasive
breast cancer,” American Journal of Surgery, vol. 191, no. 6, pp.
761–766, 2006.
[9] N. Klauber-De More, L. K. Tan, L. Lieberman et al., “Sentinel
lymph node biopsy:is it indicated in patients with high-risk
ductal carcinoma-in-situ and ductal carcinoma-in-situ with
microinvasion?” Annals of Surgical Oncology, vol. 7, pp. 636–
642, 2000.
[10] P. Veronesi, M. Intra, A. R. Vento et al., “Sentinel lymph node
biopsy for localised ductal carcinoma in situ?” Breast, vol. 14,
no. 6, pp. 520–522, 2005.
[11] H. S. Cody and K. J. Van Zee, “Point: sentinel lymph node
biopsy is indicated for patients with DCIS,” Journal of the
NationalComprehensiveCancerNetwork,vol.1,no.2,pp.199–
206, 2003.
[12] T. W. F. Yen, K. K. Hunt, M. I. Ross et al., “Predictors of
invasive breast cancer in patients with an initial diagnosis of
ductal carcinoma in situ: a guide to selective use of sentinel
lymph node biopsy in management of ductal carcinoma in
situ,” Journal of the American College of Surgeons, vol. 200, no.
4, pp. 516–526, 2005.
[ 1 3 ]B .A n s a r i ,S .A .O g s t o n ,C .A .P u r d i e ,D .J .A d a m s o n ,D .
C. Brown, and A. M. Thompson, “Meta-analysis of sentinel
node biopsy in ductal carcinoma in situ of the breast,” British
Journal of Surgery, vol. 95, no. 5, pp. 547–554, 2008.
[14] H. J. Burstein, K. Polyak, J. S. Wong, S. C. Lester, and C. M.
Kaelin, “Ductal carcinoma in situ of the breast,” New England
Journal of Medicine, vol. 350, no. 14, pp. 1430–1441, 2004.
[15] M. D. Lagios and M. J. Silverstein, “Sentinel node biopsy for
patients with DCIS: a dangerous and unwarranted direction,”
Annals of Surgical Oncology, vol. 8, no. 4, pp. 275–277, 2001.
[16] T. A. Kelly, J. A. Kim, R. Patrick, S. Grundfest, and J. P.
Crowe, “Axillary lymph node metastases in patients with a
ﬁnal diagnosis of ductal carcinoma in situ,” American Journal
of Surgery, vol. 186, no. 4, pp. 368–370, 2003.
[ 1 7 ]E .A .F a r k a s ,A .J .S t o l i e r ,S .C .T e n g ,J .S .B o l t o n ,a n dG .
M. Fuhrman, “An argument against routine sentinel node
mapping for DCIS,” American Surgeon,v o l .7 0 ,n o .1 ,p p .1 3 –
17, 2004.
[ 1 8 ]J .C .C .T a n ,D .R .M c C r e a d y ,A .M .E a s s o n ,a n dW .L .L e o n g ,
“Role of sentinel lymph node biopsy in ductal carcinoma-in-
situ treated by mastectomy,” Annals of Surgical Oncology, vol.
14, no. 2, pp. 638–645, 2007.
[19] F. Aydogan, V. Ozben, V. Celik et al., “Radioguided occult
lesion localization (roll) for non-palpable breast cancer: a
comparison between day-before and same-day protocols,”
Breast, vol. 19, no. 3, pp. 226–230, 2010.
[20] S.B.Edge,D.R.Byrd,C.C.Compton,A.G.Fritz,F.L.Greene,
and A. Trotti, Eds., AJCC Cancer Staging Handbook, Springer,
7th edition, 2009.
[21] P. P. Rosen and H. Oberman, Tumors of the Mammary
Gland. Mammary Gland, Armed Forces Institute of Pathology,
Washington, DC, USA, 1993.
[22] R. Holland, J. L. Peterse, R. R. Millis et al., “Ductal carsinoma
in situ: a proposal for a new classiﬁcation,” Seminars in
Diagnostic Pathology, vol. 11, pp. 167–180, 1994.
[23] M. J. Silverstein, K. A. Skinner, and T. J. Lomis, “Predicting
axillary nodal positivity in 2282 patients with breast carci-
noma,” World Journal of Surgery, vol. 25, no. 6, pp. 767–772,
2001.
[ 2 4 ]E .A .M i t t e n d o r f ,C .A .A r c i e r o ,V .G u t c h e l l ,J .H o o k e ,a n dC .
D. Shriver, “Core biopsy diagnosis of ductal carcinoma in situ:6 ISRN Surgery
an indication for sentinel lymph node biopsy,” Current
Surgery, vol. 62, no. 2, pp. 253–257, 2005.
[25] M. Intra, P. Veronesi, G. Mazzarol et al., “Axillary sentinel
lymph node biopsy in patients with pure ductal carcinoma in
situ of the breast,” Archives of Surgery, vol. 138, no. 3, pp. 309–
313, 2003.
[ 2 6 ]S .P e n d a s ,E .D a u w a y ,R .G i u l i a n o ,N .K u ,C .E .C o x ,a n dD .
S. Reintgen, “Sentinel node biopsy in ductal carcinoma in situ
patients,” Annals of Surgical Oncology, vol. 7, no. 1, pp. 15–20,
2000.
[27] S. L. Wong, C. Chao, M. J. Edwards et al., “Frequency of sen-
tinel lymph node metastases in patients with favorable breast
cancer histologic subtypes,” American Journal of Surgery, vol.
184, no. 6, pp. 492–498, 2002.
[28] L.H.SobinandC.Wittekind,TNMClassiﬁcationofMalignant
Tumours, UICC, Wiley-Diss, New York, NY, USA, 2002.
[29] R. J. Jackman, F. Burbank, S. H. Parker et al., “Stereotactic
breast biopsy of nonpalpable lesions: determinants of ductal
carcinoma in situ underestimation rates,” Radiology, vol. 218,
no. 2, pp. 497–502, 2001.
[ 3 0 ]L .N .B r o e k h u i z e n ,J .H .W i j s m a n ,J .L .P e t e r s e ,a n dE .J .T .
Rutgers, “The incidence and signiﬁcance of micrometastases
in lymph nodes of patients with ductal carcinoma in situ
and t1a carcinoma of the breast,” European Journal of Surgical
Oncology, vol. 32, no. 5, pp. 502–506, 2006.
[ 3 1 ]J .F .L a t a ,S .M .Y o u n g ,R .E .V e l i l l a ,E .J .S a n t o r o ,a n dS .F .
Templeton, “The relevance of occult axillary micrometastasis
in ductal carcinoma in situ: a clinicopathologic study with
long-term follow-up,” Cancer, vol. 98, no. 10, pp. 2105–2113,
2003.
[32] I. J. Bleiweiss, C. S. Nagi, and S. Jaﬀer, “Axillary sentinel lymph
nodes can be falsely positive due to iatrogenic displacement
and transport of benign epithelial cells in patients with breast
carcinoma,” Journal of Clinical Oncology, vol. 24, no. 13, pp.
2013–2018, 2006.
[33] C. H. Lee, D. Carter, L. E. Philpotts et al., “Ductal carcinoma
in situ diagnosed with stereotactic core needle biopsy: can
invasionbepredicted?”Radiology,vol.217,no.2,pp.466–470,
2000.
[ 3 4 ]M .L .R .D a r l i n g ,D .N .S m i t h ,S .C .L e s t e re ta l . ,“ A t y p i c a l
ductal hyperplasia and ductal carcinoma in situ as revealed by
large-core needle breast biopsy: results of surgical excision,”
American Journal of Roentgenology, vol. 175, no. 5, pp. 1341–
1346, 2000.
[35] L. E. Hoorntje, M. E. I. Schipper, P. H. M. Peeters, F. Bellot, R.
K. Storm, and I. H. M. Borel Rinkes, “The ﬁnding of invasive
cancer after a preoperative diagnosis of ductal carcinoma-
in-situ: causes of ductal carcinoma-in-situ underestimates
with stereotactic 14-gauge needle biopsy,” Annals of Surgical
Oncology, vol. 10, no. 7, pp. 748–753, 2003.
[36] M. F. Dillon, C. M. Quinn, E. W. McDermott, A. O’Doherty,
N. O’Higgins, and A. D. K. Hill, “Diagnostic accuracy of core
biopsy for ductal carcinoma in situ and its implications for
surgical practice,” Journal of Clinical Pathology, vol. 59, no. 7,
pp. 740–743, 2006.
[37] M. J. C. Bagnall, A. J. Evans, A. R. M. Wilson et al., “Predicting
invasion in mammographically detected microcalciﬁcation,”
Clinical Radiology, vol. 56, no. 10, pp. 828–832, 2001.
[38] J. P. Crowe, R. J. Patrick, L. A. Rybicki et al., “Does ultrasound
core breast biopsy predict histologic ﬁnding on excisional
biopsy?” American Journal of Surgery, vol. 186, no. 4, pp. 397–
399, 2003.
[39] P. Meijnen, H. S. A. Oldenburg, C. E. Loo, O. E. Nieweg, J.
L. Peterse, and E. J. T. Rutgers, “Risk of invasion and axillary
lymph node metastasis in ductal carcinoma in situ diagnosed
by core-needle biopsy,” British Journal of Surgery, vol. 94, no.
8, pp. 952–956, 2007.
[40] A. Goyal, A. Douglas-Jones, I. Monypenny, H. Sweetland, G.
Stevens, and R. E. Mansel, “Is there a role of sentinel lymph
nodebiopsyinductalcarcinomainsitu?Analysisof587cases,”
Breast Cancer Research and Treatment, vol. 98, no. 3, pp. 311–
314, 2006.
[41] L. Huo, N. Sneige, K. K. Hunt, C. T. Albarracin, A. Lopez,
and E. Resetkova, “Predictors of invasion in patients with
core-needle biopsy-diagnosed ductal carcinoma in situ and
recommendations for a selective approach to sentinel lymph
node biopsy in ductal carcinoma in situ,” Cancer, vol. 107, no.
8, pp. 1760–1768, 2006.
[ 4 2 ] Y .W a h e d n a ,A .J .E v a n s ,S .E .P i n d e r ,I .O .E l l i s ,R .W .B l a m e y ,
and J. G. Geraghty, “Mammographic size of ductal carcinoma
in situ does not predict the presence of an invasive focus,”
European Journal of Cancer, vol. 37, no. 4, pp. 459–462, 2001.
[43] K. Polom, D. Murawa, J. Wasiewicz, W. Nowakowski, and
P. Murawa, “The role of sentinel node biopsy in ductal
carcinoma in situ of the breast,” European Journal of Surgical
Oncology, vol. 35, no. 1, pp. 43–47, 2009.
[ 4 4 ]C .H .M .v a nD e u r z e n ,M .G .G .H o b b e l i n k ,R .v a nH i l l e g e r s -
berg, and P. J. van Diest, “Is there an indication for sentinel
node biopsy in patients with ductal carcinoma in situ of the
breast? a review,” European Journal of Cancer,v o l .4 3 ,n o .6 ,
pp. 993–1001, 2007.